In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Members will obtain treatment until condition progression or even the individuals are not able to tolerate the study drugs. Feasible new techniques for the diagnosis and treatment of AML. (A) The https://abbv-744drugdevelopmentpr03467.blogdun.com/32639436/abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers-secrets